Breaking News, Collaborations & Alliances

Takeda Inks $100M Pact With GammaDelta

Objective is to advance tissue-derived gamma delta (γδ) T cells

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda and GammaDelta Therapeutics have formed a collaboration to develop GammaDelta Therapeutics’ novel T cell platform, which is based on the unique properties of gamma delta (γδ) T cells derived from human tissues. The companies intend to use this novel platform to discover and develop new immunotherapies, with the aim of treating a broad range of cancers, including solid tumors, and autoinflammatory diseases. Takeda will commit up to $100 million in funding to accelerate GammaDelta The...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters